Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024Globe Newswire • 24 days ago
Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by CM-101...
Chemomab Therapeutics Ltd. (NASDAQ:CMMB Get Free Report) saw a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 244,300...
Chemomab Therapeutics (NASDAQ:CMMB Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts consensus...
Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01...
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference PR Newswire TEL AVIV, Israel, March 5, 2024 TEL...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases Chemomab Awarded New Patents for CM-101, Its First-in Class...
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results...